Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | USP10 | Q14694 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.50 |
| ▸ | USP13 | Q92995 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7500991 | 0.84 | PDE5A (0.67) | PDE5AUSP10PIK3C3USP13SMN1; SMN2 | |
| SCHEMBL7502624 | 0.81 | PDE5A (0.62) | PDE5ALMNAUSP10PIK3C3USP13 | |
| SCHEMBL7494566 | 0.80 | PDE5A (1.00) | PDE5ASMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL7502613 | 0.80 | PDE5A (0.61) | PDE5ALMNAUSP10PIK3C3USP13 | |
| SCHEMBL7504734 | 0.79 | PDE5A (0.60) | PDE5ALMNAUSP10PIK3C3USP13 | |
| SCHEMBL7496274 | 0.73 | PDE5A (0.63) | PDE5AUSP10PIK3C3USP13SMN1; SMN2 | |
| SCHEMBL9921508 | 0.72 | HTT (0.74) | PDE5ALMNAUSP10PIK3C3USP13 | |
| Hydrochloric Acid SCHEMBL27452405 | 0.72 | STAT1 (0.69) | PDE5ASMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL13170968 | 0.72 | EGFR (0.67) | PDE5ALMNASMN1; SMN2CLK4MAPK1 | |
| SCHEMBL4357604 | 0.71 | RET (0.63) | LMNASMN1; SMN2MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744501-B1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-11-30 | — | — | EP | claimed |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-24 | — | — | US | claimed |
| EP-2744501-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-06-25 | — | — | EP | claimed |
| WO-2013025958-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-21 | — | — | WO | claimed |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-21 | — | — | US | disclosed |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| US-9994529-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-9604938-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| EP-2744501-B1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2744501-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013025958-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-21 | — | — | WO | disclosed |
| EP-0607439-B1 | NITROGENOUS HETEROCYCLIC COMPOUND | EISAI CO LTD (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6046206-A | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives | CELL PATHWAYS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | PDE5A 1424/4885LMNA 3043/4885USP10 2859/4885 |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | PDE5A 1424/4885LMNA 3043/4885USP10 2859/4885 |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | PDE5A 1424/4885LMNA 3043/4885USP10 2859/4885 |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | ABL1, MAP3K3, MAP4K2 | PDE5A 1424/4885LMNA 3043/4885USP10 2859/4885 |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | PDE5A 1338/4885LMNA 3394/4885USP10 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.